Podcast: US FDA’s ‘Within Label’ Definition Allows Companies To Elaborate On Indications
Executive Summary
Permitted speech for approved products could shift dramatically depending on how hard a Trump FDA Commissioner pushes, but the expansion at the end of the Obama Administration is a significant step in its own right – one that former Commissioner Rob Califf emphasizes in an interview that is also available as a podcast.
You may also be interested in...
FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival
Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.
Off-Label Communication: When Does It Align With Approved Labeling?
US FDA draft guidance offers three-factor test to determine when communication about a medical product is consistent with labeling; information on patient-reported outcomes and mechanism of action are okay.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.